Fulgent Genetics, Inc.

Fulgent is a technology-focused healthcare company operating two primary segments: laboratory services and therapeutic development. Its laboratory business provides anatomic pathology, precision diagnostics including next-generation sequencing, specialized oncology testing, and biopharmaceutical research services, alongside a consumer telemedicine platform called Picture. In its therapeutic segment, the company develops cancer drug candidates and antibody-drug conjugates utilizing a nano-drug encapsulation platform. Fulgent serves institutional clients, including hospitals, healthcare centers, commercial laboratories, government agencies, and corporations, as well as pharmaceutical firms, contract research organizations, health insurers, and individual patients.

The company operates clinical testing facilities in California, Texas, Georgia, Massachusetts, and Arizona, as well as an international laboratory in Australia. It conducts clinical trials for its therapeutic assets across trial sites within the United States. In addition, its intellectual property portfolio covers multiple jurisdictions, including the United States, Canada, China, Japan, Australia, New Zealand, and several European nations. The text does not disclose the specific location of the company's corporate headquarters.

Summary of the business section of Fulgent Genetics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“Our dedicated and growing team of over 1,300 employees is a source of pride.”